hVIVO plc (LON:HVO - Get Free Report) shares were up 13.2% during mid-day trading on Monday . The stock traded as high as GBX 9.89 ($0.13) and last traded at GBX 9.85 ($0.13). Approximately 27,466,316 shares were traded during mid-day trading, an increase of 651% from the average daily volume of 3,655,778 shares. The stock had previously closed at GBX 8.70 ($0.12).
Wall Street Analyst Weigh In
Separately, Shore Capital restated a "buy" rating on shares of hVIVO in a research note on Friday.
Read Our Latest Research Report on HVO
hVIVO Trading Down 2.8%
The firm has a market cap of £73.59 million, a price-to-earnings ratio of 4.29 and a beta of 0.97. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The business's fifty day moving average is GBX 16.08 and its two-hundred day moving average is GBX 17.93.
hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Equities analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.
Insider Activity
In related news, insider Yamin Mo' Khan sold 3,062,246 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($703,774.26). 14.03% of the stock is currently owned by company insiders.
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Further Reading
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
